Does the media prefer ADMA or ACAD?

In the previous week, ADMA Biologics had 7 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 9 mentions for ADMA Biologics and 2 mentions for ACADIA Pharmaceuticals. ADMA Biologics' average media sentiment score of 0.31 beat ACADIA Pharmaceuticals' score of 0.18 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADMA or ALLO?

In the previous week, ADMA Biologics had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 9 mentions for ADMA Biologics and 4 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.67 beat ADMA Biologics' score of 0.31 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMVT or ADMA?

In the previous week, ADMA Biologics had 7 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for ADMA Biologics and 2 mentions for Immunovant. Immunovant's average media sentiment score of 1.19 beat ADMA Biologics' score of 0.31 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KYMR or ADMA?

In the previous week, ADMA Biologics had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 9 mentions for ADMA Biologics and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.18 beat ADMA Biologics' score of 0.31 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ADMA or LNTH?

Lantheus has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $509.86M 3.67 $146.93M $0.68 11.88 Lantheus $1.55B 4.26 $233.56M $4.15 24.39

Is ADMA or LNTH more profitable?

ADMA Biologics has a net margin of 32.43% compared to Lantheus' net margin of 18.05%. ADMA Biologics' return on equity of 39.98% beat Lantheus' return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.43% 39.98% 28.08% Lantheus 18.05% 29.32% 15.00%

Does the media prefer ADMA or LNTH?

In the previous week, ADMA Biologics had 5 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for ADMA Biologics and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat ADMA Biologics' score of 0.31 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADMA Biologics (ADMA) Competitors

$8.09 +0.12 (+1.44%)

As of 12:46 PM Eastern

Compare

ADMA vs. ACAD, ALLO, IMVT, KYMR, and LNTH

Should you buy ADMA Biologics stock or one of its competitors? MarketBeat compares ADMA Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADMA Biologics include ACADIA Pharmaceuticals (ACAD), Allogene Therapeutics (ALLO), Immunovant (IMVT), Kymera Therapeutics (KYMR), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

ADMA Biologics (NASDAQ:ADMA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, ADMA Biologics had 7 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 9 mentions for ADMA Biologics and 2 mentions for ACADIA Pharmaceuticals. ADMA Biologics' average media sentiment score of 0.31 beat ACADIA Pharmaceuticals' score of 0.18 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.67	$146.93M	$0.68	11.88
ACADIA Pharmaceuticals	$1.10B	3.34	$391M	$2.20	9.72

ACADIA Pharmaceuticals has a net margin of 34.30% compared to ADMA Biologics' net margin of 32.43%. ADMA Biologics' return on equity of 39.98% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

ADMA Biologics presently has a consensus target price of $19.00, suggesting a potential upside of 135.29%. ACADIA Pharmaceuticals has a consensus target price of $31.63, suggesting a potential upside of 47.85%. Given ADMA Biologics' higher probable upside, equities analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats ADMA Biologics on 9 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Allogene Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

ADMA Biologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.67	$146.93M	$0.68	11.88
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

ADMA Biologics currently has a consensus target price of $19.00, suggesting a potential upside of 135.29%. Allogene Therapeutics has a consensus target price of $8.52, suggesting a potential upside of 366.97%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

ADMA Biologics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

ADMA Biologics has a net margin of 32.43% compared to Allogene Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Allogene Therapeutics	N/A	-56.45%	-40.36%

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, ADMA Biologics had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 9 mentions for ADMA Biologics and 4 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.67 beat ADMA Biologics' score of 0.31 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADMA Biologics beats Allogene Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Immunovant presently has a consensus price target of $37.33, suggesting a potential upside of 20.03%. ADMA Biologics has a consensus price target of $19.00, suggesting a potential upside of 135.29%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, ADMA Biologics had 7 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for ADMA Biologics and 2 mentions for Immunovant. Immunovant's average media sentiment score of 1.19 beat ADMA Biologics' score of 0.31 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
ADMA Biologics	$509.86M	3.67	$146.93M	$0.68	11.88

47.1% of Immunovant shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ADMA Biologics has a net margin of 32.43% compared to Immunovant's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
ADMA Biologics	32.43%	39.98%	28.08%

Summary

ADMA Biologics beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does ADMA Biologics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

75.7% of ADMA Biologics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kymera Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	119.03	-$311.35M	-$3.57	N/A
ADMA Biologics	$509.86M	3.67	$146.93M	$0.68	11.88

Kymera Therapeutics currently has a consensus target price of $118.10, suggesting a potential upside of 58.55%. ADMA Biologics has a consensus target price of $19.00, suggesting a potential upside of 135.29%. Given ADMA Biologics' higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

ADMA Biologics has a net margin of 32.43% compared to Kymera Therapeutics' net margin of -611.94%. ADMA Biologics' return on equity of 39.98% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
ADMA Biologics	32.43%	39.98%	28.08%

In the previous week, ADMA Biologics had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 9 mentions for ADMA Biologics and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.18 beat ADMA Biologics' score of 0.31 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to Lantheus?

ADMA Biologics (NASDAQ:ADMA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

ADMA Biologics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

Lantheus has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.67	$146.93M	$0.68	11.88
Lantheus	$1.55B	4.26	$233.56M	$4.15	24.39

ADMA Biologics has a net margin of 32.43% compared to Lantheus' net margin of 18.05%. ADMA Biologics' return on equity of 39.98% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Lantheus	18.05%	29.32%	15.00%

ADMA Biologics currently has a consensus price target of $19.00, indicating a potential upside of 135.29%. Lantheus has a consensus price target of $101.86, indicating a potential upside of 0.65%. Given ADMA Biologics' higher possible upside, equities analysts clearly believe ADMA Biologics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, ADMA Biologics had 5 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for ADMA Biologics and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat ADMA Biologics' score of 0.31 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Lantheus beats ADMA Biologics on 9 of the 16 factors compared between the two stocks.

Get ADMA Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADMA vs. The Competition

Export

Metric	ADMA Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.87B	$3.32B	$6.47B	$12.13B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	11.85	19.26	23.95	23.84
Price / Sales	3.67	176.98	486.59	88.09
Price / Cash	12.18	51.45	26.99	37.25
Price / Book	4.02	8.12	10.43	6.77
Net Income	$146.93M	$23.89M	$3.57B	$337.72M
7 Day Performance	2.22%	-5.34%	-0.97%	-2.97%
1 Month Performance	-1.16%	2.55%	3.55%	1.70%
1 Year Performance	-60.82%	37.30%	24.16%	27.34%

ADMA Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADMA ADMA Biologics	4.5831 of 5 stars	$8.09 +1.4%	$19.00 +135.0%	-61.3%	$1.87B	$509.86M	11.89	530
ACAD ACADIA Pharmaceuticals	3.9202 of 5 stars	$21.52 -0.6%	$31.63 +47.0%	-1.9%	$3.71B	$1.10B	9.78	510
ALLO Allogene Therapeutics	2.9265 of 5 stars	$2.15 -0.9%	$8.52 +296.4%	+32.4%	$748.98M	$20K	N/A	310	News Coverage
IMVT Immunovant	2.6482 of 5 stars	$32.86 -1.3%	$37.33 +13.6%	+85.5%	$6.84B	N/A	N/A	120
KYMR Kymera Therapeutics	2.2866 of 5 stars	$78.47 -3.6%	$118.10 +50.5%	+55.7%	$6.70B	$39.21M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADMA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, IMVT, KYMR, and LNTH

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Summary

How does ADMA Biologics compare to Immunovant?

Summary

How does ADMA Biologics compare to Kymera Therapeutics?

Summary

How does ADMA Biologics compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, IMVT, KYMR, and LNTH

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Does the media prefer ADMA or ACAD?

Which has more risk & volatility, ADMA or ACAD?

Which has better earnings and valuation, ADMA or ACAD?

Is ADMA or ACAD more profitable?

Do analysts recommend ADMA or ACAD?

Do institutionals and insiders have more ownership in ADMA or ACAD?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Which has better valuation & earnings, ADMA or ALLO?

Do analysts rate ADMA or ALLO?

Which has more volatility and risk, ADMA or ALLO?

Is ADMA or ALLO more profitable?

Do insiders & institutionals hold more shares of ADMA or ALLO?

Does the media refer more to ADMA or ALLO?

Summary

How does ADMA Biologics compare to Immunovant?

Which has more volatility & risk, IMVT or ADMA?

Do analysts recommend IMVT or ADMA?

Does the media prefer IMVT or ADMA?

Which has better valuation & earnings, IMVT or ADMA?

Do institutionals & insiders hold more shares of IMVT or ADMA?

Is IMVT or ADMA more profitable?

Summary

How does ADMA Biologics compare to Kymera Therapeutics?

Do insiders and institutionals hold more shares of KYMR or ADMA?

Which has more volatility and risk, KYMR or ADMA?

Which has stronger valuation & earnings, KYMR or ADMA?

Do analysts prefer KYMR or ADMA?

Is KYMR or ADMA more profitable?

Does the media prefer KYMR or ADMA?

Summary

How does ADMA Biologics compare to Lantheus?

Which has more volatility and risk, ADMA or LNTH?

Which has stronger valuation & earnings, ADMA or LNTH?

Is ADMA or LNTH more profitable?

Do analysts recommend ADMA or LNTH?

Does the media prefer ADMA or LNTH?

Do institutionals and insiders believe in ADMA or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools